Type:
Whole Allergen
Whole Allergen
Whole Allergen
Morphine
c260
Oral
Genuine IgE-mediated allergies to opiates (morphine, codeine) remain rare notwithstanding their frequent and universal use.(1) It has been shown that morphine can be used to detect IgE antibodies against various neuromuscular blocking agents (NMBAs) enabling it to be used as a marker allergen for NMBA sensitization.(2) Cross-reactivity between different NMBA is common since they all share the quaternary ammonium ion allergenic epitope.(3) NMBAs represent a significant cause of anesthesia-related anaphylaxis(1), which is rare but can be severe.(4) Diagnostic approach of anesthesia-related IgE-mediated immediate hypersensitivity reactions (IHR) generally starts with patient’s history, thorough review of the anesthetic/surgical notes complemented with skin prick testing and/or in vitro quantification of specific IgE (sIgE) antibodies.(1)
Morphine is a natural alkaloid that is derived from opium papaver somniferum poppy seeds resin extracts. It has potent and profound analgesic effects and it has been used in clinical medicine for almost two hundred years.(5) Morphine acts by engagement in cell surface opiate receptors (predominant µ type receptors) that are found in the central nervous system, but also heart, lung, vascular and intestinal cells. Current indications are for severe pain, pre- and postoperative analgesia, control of pain from angina pectoris or acute myocardial infarction and therapy of pulmonary edema.
Many opioids are potent histamine releasers producing a variety of hemodynamic changes and anaphylactoid reactions, but the relationship of the appearance of these effects to the histamine plasma concentration is complex and there is no direct and invariable relationship between the two. Morphine has multiple direct effects on the vasculature and other hemodynamically-active mediators released along with histamine contribute to the variable responses to opioid drug administration.(6)
The structure of morphine is similar to the quaternary ammonium ion found in neuromuscular blocking agents (NMBAs), which contains a hydrophobic ring skeleton and a hydrophilic tertiary amine. It is well known that morphine is a potent inhibitor of the binding in vitro of IgE antibodies to NMBAs in sera from some subjects who had experienced an anaphylactic reaction following exposure to these drugs during anesthesia. The mechanism of this inhibition has been shown to be cross-reactive recognition of substituted ammonium groups which are shared by the NMBDs, morphine and a number of other drugs and chemicals. It has been shown that morphine can be used to detect IgE antibodies against various NMBAs, enabling it to be used as a marker allergen for NMBA sensitization.(2)
Opioids such as morphine, codeine and pethidine provoke non-specific wheals in the skin by causing direct degranulation of mast cells without the involvement of either opioid receptors or opioid-specific IgE antibodies.(6) Genuine IgE-mediated allergies to opiates (morphine, codeine) remain rare notwithstanding their frequent and universal use. Additionally, correct diagnosis is not straightforward, mainly because of uncertainties associated with measurement of drug-specific IgE antibodies and skin testing.(1)
Anaphylaxis during general anesthesia is rare but can be severe, as it is often complicated by significant morbidity. Identification of the cause of anaphylaxis may pose a significant dilemma to the allergist and anesthetist. Results from a study in the UK showed that when the drug culprit of anaphylaxis was detected, morphine represented 4.8% of the cases (where NMBA represented 38.1%).(4)
In many countries, curarizing NMBAs represent a significant cause of anesthesia-related anaphylaxis.(1) Allergy to neuromuscular blocking agents (NMBA) constitutes a major cause of potentially life-threatening perioperative anaphylaxis. In a study which considered 344 patients, NMBA accounted for 40% of all patients with an IgE-mediated perioperative allergy.(9) However other studies showed even higher values (up to 60%).(8)
In a well-known study in Scandinavian countries showed that IgE antibodies to morphine are common in healthy individuals and among patients prone to become IgE-sensitized in Norway, where allergic anaphylaxis to NMBA drugs is prevalent, and considerably less so in Sweden, where anaphylactic reactions are rarely reported.(10) Another survey showed that the mortality rate from an immediate hypersensitivity reaction to NMBA administration was relatively high (4.1%) in France over the period 2000–2011.(11)
One of the major uncertainties in evaluating diagnostic test results in suspected cases of anaphylaxis to anesthetic drugs is the possibility that a negative result to the suspected drug(s) may occur in a subject who experienced some or all of the signs associated with an anaphylactic or anaphylactoid reaction due to another, non-allergic, mechanism. In such cases it is difficult to determine whether the result is due to a weakness inherent in the test, such as lack of sensitivity, or whether the negative finding truly reflects the real situation.(2)
The gold standard to ascertain correct diagnosis of immediate hypersensitivity reactions (IHR) to drugs is a controlled drug provocation test (DPT) with the culprit compound(s). However, DPTs entail a risk of severe, life-threatening complications and can be contraindicated (e.g. patients having suffered from life-threatening reactions) or impossible (e.g., full-dose DPT in hypersensitivity to curarizing neuromuscular blocking agents (NMBA)). Moreover, the predictive value of DPTs is not known and DPTs might yield false negative results. Therefore, the diagnostic approach of anesthesia-related IgE-mediated IHR generally starts with patient’s history, thorough review of the anesthetic/surgical notes complemented with skin testing and/or in vitro quantification of specific IgE (sIgE) antibodies. (1)
Some sources report that an isolated positive sIgE result for morphine does not serve as a reliable predictor for genuine NMBA allergy. The exact reason(s) remains elusive but probably relate(s) to the (mostly unknown) origin and extremely heterogeneous specificity of (highly cross-reactive) NMBA sIgE antibodies and non-specific binding to the allergosorbent by high total IgE levels.(9)
Erroneous opiate allergy diagnosis might not only entail unnecessary avoidance measures but also, most importantly, ultimately put patients at risk by overlooking alternative diagnoses such as an allergy to rocuronium or suxamethonium (1) or, possibly, other compounds as antibiotics or chlorhexidine. (4)
In cases of non-IgE-mediated IHR, diagnosis might benefit from cellular tests such as basophil mediator release tests and basophil activation tests (BAT). (1)
Cross-reactivity between different NMBA is common since they all share the quaternary ammonium ion allergenic epitope(3). However, the extent of cross-reactivity varies considerably between patients and it is unusual for an individual to be allergic to all NMBA(12). The explanation for this limitation in cross-reactivity is that IgE antibody paratopes may not only recognize the quaternary ammonium ion; sometimes the molecular environment around the ammonium ion is also part of the allergenic epitope(10). The possibility of multiple allergies should therefore be considered.
Cross-inhibition results indicate that some patients have IgE not only against the ammonium ion but also against the hydrophobic part of the morphine molecule.(8)
Author: Dr. Fabio Iachetti
Reviewer: Dr. Christian Fischer
Last reviewed: August 2020
1. Ebo DG, Faber M, Elst J, Van Gasse AL, Bridts CH, Mertens C, et al. In Vitro Diagnosis of Immediate Drug Hypersensitivity During Anesthesia: A Review of the Literature. The Journal of Allergy and Clinical Immunology: In Practice. 2018;6(4):1176-84.
2. Fisher MM, Baldo BA. Immunoassays in the diagnosis of anaphylaxis to neuromuscular blocking drugs: the value of morphine for the detection of IgE antibodies in allergic subjects. Anaesth Intensive Care. 2000;28(2):167-70.
3. Mertes PM, Laxenaire MC, Alla F, Groupe d'Etudes des Reactions Anaphylactoides P. Anaphylactic and anaphylactoid reactions occurring during anesthesia in France in 1999-2000. Anesthesiology. 2003;99(3):536-45.
4. Meng J, Rotiroti G, Burdett E, Lukawska JJ. Anaphylaxis during general anaesthesia: experience from a drug allergy centre in the UK. Acta Anaesthesiol Scand. 2017;61(3):281-9.
5. Morphine. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD)2012.
6. Baldo BA, Pham NH. Histamine-releasing and allergenic properties of opioid analgesic drugs: resolving the two. Anaesth Intensive Care. 2012;40(2):216-35.
7. Cooper TE, Chen J, Wiffen PJ, Derry S, Carr DB, Aldington D, et al. Morphine for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;5:CD011669.
8. Armentia A, Ruiz-Munoz P, Quesada JM, Postigo I, Herrero M, Martin-Gil FJ, et al. Clinical value of morphine, pholcodine and poppy seed IgE assays in drug-abusers and allergic people. Allergol Immunopathol (Madr). 2013;41(1):37-44.
9. Leysen J, Uyttebroek A, Sabato V, Bridts CH, De Clerck LS, Ebo DG. Predictive value of allergy tests for neuromuscular blocking agents: tackling an unmet need. Clin Exp Allergy. 2014;44(8):1069-75.
10. Florvaag E, Johansson SG, Oman H, Venemalm L, Degerbeck F, Dybendal T, et al. Prevalence of IgE antibodies to morphine. Relation to the high and low incidences of NMBA anaphylaxis in Norway and Sweden, respectively. Acta Anaesthesiol Scand. 2005;49(4):437-44.
11. Reitter M, Petitpain N, Latarche C, Cottin J, Massy N, Demoly P, et al. Fatal anaphylaxis with neuromuscular blocking agents: a risk factor and management analysis. Allergy. 2014;69(7):954-9.
12. Ebo DG, Fisher MM, Hagendorens MM, Bridts CH, Stevens WJ. Anaphylaxis during anaesthesia: diagnostic approach. Allergy. 2007;62(5):471-87.